Rockwell Medical (RMTI) Q3 2026 earnings review
Rockwell Medical sales climb 20%, but its gross margin shrinks
Rockwell Medical grew its dialysis supply sales in the third quarter, but manufacturing costs rose faster and widened its losses. Net sales climbed 20% from a year ago to $19 million as clinics in the western United States bought more concentrates. Yet gross margin slipped from the second quarter to 16%, and cash fell by $2 million. Chief executive Mark Strobeck also announced a deal to buy Vantive's dialysis business, which would lift annual sales above $400 million.
| Net sales | $19.1M +20% from a year ago |
|---|---|
| Gross margin | 16.3% down from 18.2% last quarter |
| Adjusted EBITDA | -$0.27M +$0.05M a year ago |
| Projected combined revenue | $400–450M with pending Vantive deal |
⚖️ Verdict: 🔴 Bearish
The standalone story got worse because the expected second-half profit rebound went backward. Newly automated factory lines were supposed to lift gross margin toward the 18% to 22% full-year plan, but margin dropped instead and the press release left out the 2026 outlook table. By our math, Rockwell now needs $1.7 million of fourth-quarter Adjusted EBITDA just to reach the bottom of its prior annual plan.
The question now is how the company will pay for the Vantive acquisition and whether that business makes money. Buying a profitable global equipment business without issuing cheap stock would solve Rockwell's scale problem, while taking on a loss-making factory with heavy debt would strain its $23 million cash balance. The acquisition filing and conference call will tell.
🐂 Bull Case
Western U.S. Clinics Keep Lifting Sales
Rockwell Medical makes liquid and dry chemical concentrates that dialysis clinics use to clean patients' blood. After losing most of its business with its largest customer last year, the healthcare supplier has rebuilt revenue by signing clinics in the western United States and raising prices on renewed contracts. Third-quarter net sales reached $19.1 million, up 20.1% from a year ago and up 7.5% from the second quarter.
The company said growth came from "greater purchasing from our existing customers and additional sales to new customers in the western United States". That sequential gain matters because the second quarter included a one-time order from DaVita, a major dialysis chain. Growing past that order shows that underlying clinic demand is still expanding.
What to watch: the exact dollar sales from western U.S. clinics in the quarterly filing. A figure at or above the second quarter's $1.3 million gain would show that new clinics are sticking with the supplier.
🐻 Bear Case
Gross Margin Slipped Despite Factory Automation
Rockwell turned on two automated liquid production lines in the second quarter and said they would lift annual gross profit by more than $3 million. Supporters viewed factory automation as a rising profit driver, while skeptics warned that any hiccup would put the full-year margin target of 18% to 22% out of reach. This quarter tested the skeptics' view, because gross margin fell back to 16.3% from 18.2% in the second quarter.
The supplier pointed out that gross margin rose from 14.3% a year ago. But last year's third quarter included $560,000 of plant closure and severance charges. Excluding those one-offs, last year's gross margin was 17.8% by our math, so underlying profitability actually shrank by 1.5 percentage points.
Cost of sales, the expense of making and shipping the concentrates, rose by 2.0 percentage points of revenue from the second quarter to 83.7%. Nine-month gross margin sits at 17.1%. By our math, Rockwell now needs a 21.3% margin in the fourth quarter just to reach the bottom of its 18% annual plan.
What to watch: fourth-quarter gross margin and commentary from finance chief Jesse Neri on the earnings call. A reading below 21% would leave the company short of its full-year margin target.
Losses Grew and the Full-Year Plan Is In Doubt
The dialysis supplier has posted a net loss in every quarter of 2025 and 2026. Earlier this year management aimed for positive net income in the second half and projected $1.0 million to $2.0 million in full-year Adjusted EBITDA, a measure of operating cash profit excluding one-offs. Instead, the third-quarter net loss widened to $2.3 million from $1.8 million a year ago.
- Transaction-related expenses: $847,000, or 4.4% of net sales, up from zero a year ago
- Net loss excluding transaction expenses: $1.5 million by our math, wider than the second quarter's $1.2 million loss
- Adjusted EBITDA: negative $267,000, down from positive $50,000 a year ago and negative $153,000 in the second quarter
- Nine-month Adjusted EBITDA: negative $714,000, leaving $1.7 million needed in the fourth quarter to hit the $1.0 million annual floor
The press release also omitted the full-year outlook table that Rockwell published in prior quarters. Even if the company still stands by its earlier targets on the conference call, earning $1.7 million of Adjusted EBITDA in one quarter would require nearly double the $967,000 it made in the fourth quarter of 2025.
What to watch: whether management reiterates or cuts the 2026 Adjusted EBITDA target on the call. Holding the target without a fourth-quarter margin surge would strain the plan.
Cash Burn Resumed Ahead of Debt Payments
Bulls previously pointed to positive operating cash flow in the second quarter as proof that the business could fund itself. Bears worried about ongoing losses and $3.9 million of term loan repayments starting in February 2027. In the third quarter, cash and investments fell by $2.3 million to $22.5 million, down from $24.8 million in June.
Rockwell said the drop came from higher customer bills waiting to be collected, prepaid expenses, and "capital purchases to further automate our manufacturing facilities". Taking on a major foreign acquisition while the standalone business consumes cash leaves less room for error before debt payments begin next year.
What to watch: the nine-month operating cash flow line in the quarterly filing. A negative third-quarter cash flow reading would put the full-year positive operating cash flow target at risk.
Risks This Quarter Didn't Answer
Three standing business risks received no new numbers in the earnings release and depend on the quarterly filing or conference call.
- DaVita contract expiration: the one-year supply extension ends on December 31, 2026, and any non-renewal would remove roughly 7% to 8% of standalone sales.
- Competitor recovery in the West: the release did not state how much revenue came from western U.S. clinics, which is needed to test whether gains from a rival's shutdown are fading.
- Customer concentration: three customers each accounted for 8% to 11% of sales last quarter, and the concentration table only appears in the quarterly filing.
👓 Other Themes
Vantive Deal Would Multiply Revenue Sixfold
After the quarter ended, Rockwell agreed to buy Vantive's hemodialysis concentrates, AK-98 dialysis machines, water treatment systems, and a one-million-square-foot factory in Medolla, Italy. Chief executive Mark Strobeck called the deal "a transformational step that we believe will significantly expand our portfolio and global reach". The combined business is "projected to generate annual revenue between $400 million and $450 million", about six times Rockwell's standalone sales, though price and funding terms were not disclosed.
💲 Other KPIs
Overhead and administrative spending rose 14.3% from a year ago and 3.0% from the second quarter. Because sales grew faster, the expense dipped by 1.0 percentage point of revenue from a year ago to 19.9%, but it still absorbed more than all of the quarter's $3.11 million gross profit.
Total liabilities climbed 11.7% from the second quarter and 17.0% from a year ago, after staying near $21.5 million for two quarters. The balance sheet summary does not split out debt from unpaid supplier bills, which the quarterly filing will detail.
The basic and diluted share count rose 10.3% from a year ago because the healthcare company sold stock through its at-the-market facility in the third quarter of 2025. Share count was unchanged from the second quarter following July's 1-for-10 reverse stock split.
🔮 Guidance
New. The dialysis group projects that combining its operations with Vantive's global hemodialysis business will produce $400 million to $450 million in yearly sales, up from $54.2 million in the first nine months of 2026. The press release did not include a standalone 2026 outlook table.
❓ Key Questions
How will Rockwell pay for the Vantive acquisition?
The company has $22.5 million in cash and is buying a business with roughly $350 million in annual revenue and a one-million-square-foot Italian factory. Investors need to know the purchase price, debt terms, and whether Vantive's business is profitable.
Does management still stand by its 2026 standalone outlook?
The earnings release dropped the 2026 outlook table. Hitting the prior floors of 18% gross margin and $1.0 million in Adjusted EBITDA requires a 21.3% margin and $1.7 million of Adjusted EBITDA in the fourth quarter by our math.
Why did gross margin drop after the automated lines started?
Management activated two automated liquid production lines in the second quarter to save $3 million a year, yet gross margin fell from 18.2% to 16.3% even as sales grew 7.5% from the second quarter.
Will DaVita renew its supply contract past December 31?
The one-year contract extension with DaVita expires in seven weeks. Because DaVita also holds $15 million of preferred stock with debt-consent rights, the renewal and any financing for the Vantive deal may be linked.